Event: Friday, July 31, 2026, at 8:00 a.m. ET
Focus: Revenue execution and full-year outlook, cash runway after the litigation payment, and timing/confidence around a catalyst-heavy second half.
Moderna enters 2Q26 as a transition story rather than a quarterly earnings story. The core issue is whether the company can turn a COVID-led seasonal-vaccine base into durable growth while holding its cost base down and advancing several high-value clinical programs.
The quarter itself is seasonally small. Management’s prior outlook called for 2Q revenue of $50–100 million, approximately evenly split between U.S. and international markets. The more consequential questions are:
The stock closed July 30 at $57.94, nearly doubling from $29.49 at year-end 2025, though it has retraced materially from its July 6 closing high of $81.80. That setup suggests investors have begun to price in pipeline and platform optionality, leaving the company more exposed to a soft outlook, cash-burn disappointment, or clinical-timing slippage.
Moderna guided to $50–100 million of 2Q26 revenue, after reporting $389 million in 1Q—primarily from international deliveries under long-term government partnerships, including the U.K. spring campaign.
For perspective:
| Metric | 2Q25 actual | 2Q26 company outlook |
|---|---|---|
| Revenue | $142M | $50–100M |
| Key driver | Predominantly COVID vaccine | Roughly even U.S./international mix |
| 1H revenue | $250M | Expected $440–490M |
A year-over-year decline in the standalone quarter would not necessarily be thesis-breaking: 1Q26 benefited from the timing of international contractual deliveries, including a U.K. shipment that had shifted from 2025. Still, a result near the low end of the range—or commentary suggesting a weak fall order book—would raise the bar materially for the second half.
Key point: To reach its “up to 10% growth” objective, Moderna would need 2026 revenue of up to roughly $2.14 billion. With expected first-half revenue of $440–490 million, the company is heavily reliant on the seasonal 3Q/4Q respiratory-vaccine period.
Moderna remains loss-making as it funds a large clinical pipeline. In 1Q26, excluding the litigation charge, management cited a net loss of approximately $0.5 billion and said it was on track for:
The company also warned that R&D spending would be weighted more heavily to the second half, as would commercial spending. Accordingly, the most constructive outcome is not necessarily a low 2Q loss, but rather evidence that cost discipline remains intact without deferring or impairing pivotal programs.
Management reiterated that 2026 growth should be driven by:
Important nuances:
Questions for the call - Is the company still comfortable with “up to 10%” growth? - How much visibility does it have into 2H government and commercial orders? - Is U.S. COVID demand tracking as expected? - Is mNEXSPIKE gaining share or simply protecting revenue against a shrinking COVID market? - Is the expected 50/50 geographic mix still realistic?
Moderna’s seasonal flu vaccine, mRNA-1010, has a U.S. FDA PDUFA target action date of August 5, 2026—just five days after earnings.
That decision is strategically meaningful because it could become Moderna’s fifth approved product and validate a broader respiratory-vaccine franchise beyond COVID. In prior Phase 3 results, mRNA-1010 demonstrated superior relative vaccine efficacy versus a licensed standard-dose flu vaccine in adults aged 50 and older.
The prior U.S. regulatory process was not straightforward: Moderna had received a Refusal-to-File letter in early 2026, but subsequently obtained the August 5 PDUFA date. At 1Q earnings, management characterized interactions with the FDA review team as routine and said it remained encouraged.
What matters at earnings: Management may be limited in what it can say days before the action date, but investors should listen closely for any discussion of review status, launch preparedness, manufacturing readiness, target populations, and commercial expectations. Approval would be a platform and portfolio positive, although Moderna has not included material 2026 flu revenue in its guidance.
Cash is a central part of the thesis. Moderna ended 1Q26 with $7.5 billion in cash, cash equivalents, and investments, down from $8.1 billion at year-end 2025.
The company expects to make a $950 million cash payment in 3Q26 under its settlement with Arbutus Biopharma and Genevant Sciences. Moderna already recognized most of the accounting expense in 1Q, but the cash impact is still ahead.
Management’s current year-end cash outlook is $4.5–5.0 billion, excluding further draws on its remaining $0.9 billion credit-facility capacity.
There is also a contingent risk: if Moderna ultimately loses its government-contractor-immunity appeal under 28 U.S.C. §1498, it could owe an additional payment of up to $1.3 billion. Management has not accrued this amount because it considers a loss not probable; its prior estimate suggested a resolution could occur in late 2027 or 2028.
Investor interpretation: The $950 million payment is known and should be incorporated into the current cash outlook. The larger issue is whether the company can fund its pipeline through pivotal readouts and initial commercial launches without another financing need.
Moderna has multiple potentially value-defining milestones expected in 2026:
| Program | Expected milestone | Why it matters |
|---|---|---|
| mRNA-1010, seasonal flu | FDA action date: August 5 | Could establish a fifth approved product |
| mRNA-1403, norovirus | Phase 3 data in 2026, subject to case accrual | Large unserved vaccine market; no approved vaccine currently |
| Intismeran autogene / mRNA-4157 | Phase 3 adjuvant melanoma interim analysis potentially in 2026 | Lead oncology asset with Merck; major platform validation |
| mRNA-3927, propionic acidemia | Registrational data potentially in 2026 | Could establish rare-disease therapeutic franchise |
| mRNA-4359 | Potential Phase 2 data in 2026 | Early evidence for wholly owned oncology program |
| mRNA-1195, multiple sclerosis | Phase 1b data expected in 2H26 | Early validation of an emerging modality |
Intismeran, Moderna’s personalized cancer vaccine partnered with Merck, is the company’s highest-profile non-vaccine asset. Five-year Phase 2b data in adjuvant melanoma showed a 49% reduction in the risk of recurrence or death for intismeran plus KEYTRUDA versus KEYTRUDA alone.
The Phase 3 adjuvant melanoma trial is fully enrolled and may have an interim analysis in 2026. However, investors should recognize the distinction between a positive Phase 2 signal and a pivotal Phase 3 outcome:
The program has also expanded into earlier-stage NSCLC, renal-cell carcinoma, and bladder-cancer studies. The breadth is attractive, but it also means a substantial portion of Moderna’s future oncology valuation depends on data that remain event-driven and uncertain.
A constructive 2Q outcome would likely include:
The report could disappoint if it shows:
MRNA’s 2Q print is likely to be less important than its forward commentary. The quarter is seasonally light and was already guided to just $50–100 million in revenue. The investment debate centers on whether Moderna can credibly bridge from a declining COVID-vaccine market to a diversified commercial platform—while maintaining a sufficient cash runway to reach several pivotal data events.
The near-term setup is unusually catalyst dense:
For investors, the key question after earnings will be simple: does management still have the commercial visibility, cost control, cash runway, and clinical timing needed to make those future catalysts investable today?